CORI Pemfailan SEC - Corium International, Inc.- Laporan Tahunan, Penyata Proksi, Prospektus

Statistik Asas

LEI	549300OGJMOXT00S0K11
CIK	1594337

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Corium International, Inc.

SEC Filings (Chronological Order)

Halaman ini menyediakan senarai kronologi lengkap bagi Pemfailan SEC, tidak termasuk pemfailan pemilikan yang kami sediakan di tempat lain.

December 7, 2018	15-12B	CORI / Corium International, Inc. 15-12B UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number 001-36375 Corium International, Inc. (Exact name of registrant as specified
November 28, 2018	SC 13G/A	CORI / Corium International, Inc. / Broadfin Capital, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.
November 27, 2018	S-8 POS	CORI / Corium International, Inc. S-8 POS As filed with the Securities and Exchange Commission on November 27, 2018 Registration No.
November 27, 2018	S-8 POS	CORI / Corium International, Inc. S-8 POS As filed with the Securities and Exchange Commission on November 27, 2018 Registration No.
November 27, 2018	S-8 POS	CORI / Corium International, Inc. S-8 POS As filed with the Securities and Exchange Commission on November 27, 2018 Registration No.
November 27, 2018	S-8 POS	CORI / Corium International, Inc. S-8 POS As filed with the Securities and Exchange Commission on November 27, 2018 Registration No.
November 27, 2018	S-8 POS	CORI / Corium International, Inc. S-8 POS As filed with the Securities and Exchange Commission on November 27, 2018 Registration No.
November 27, 2018	POS AM	CORI / Corium International, Inc. S-3 As filed with the Securities and Exchange Commission on November 27, 2018 Registration No.
November 27, 2018	POS AM	CORI / Corium International, Inc. POS AM As filed with the Securities and Exchange Commission on November 27, 2018 Registration No.
November 27, 2018	POS AM	CORI / Corium International, Inc. S-3 As filed with the Securities and Exchange Commission on November 27, 2018 Registration No.
November 27, 2018	8-K	Changes in Control of Registrant, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Material Modification to Rights of Security Holders, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits, Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement, Completion of Acquisition or Disposition of Assets, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): November 26, 2018 Corium International, Inc.
November 27, 2018	EX-3.1	Amended and Restated Certificate of Incorporation of Corium International, Inc. Exhibit 3.1 FIFTH RESTATED CERTIFICATE OF INCORPORATION OF CORIUM INTERNATIONAL, INC. FIRST: The name of the corporation formed hereby is Corium International, Inc. (the “Corporation”). SECOND: The address of the Corporation’s registered office in the State of Delaware is 1209 Orange Street, in the City of Wilmington, County of New Castle, State of Delaware, 19801, and the name of the Corporation’
November 27, 2018	EX-3.2	Amended and Restated Bylaws of Corium International, Inc. Exhibit 3.2 AMENDED & RESTATED BYLAWS OF CORIUM INTERNATIONAL, INC. (a Delaware corporation) ARTICLE I Stockholders SECTION 1. Annual Meetings. The annual meeting of the stockholders of Corium International, Inc. (the “Corporation”) for the election of directors and for the transaction of such other business as may properly come before the meeting shall be held each year at such date and time, wit
November 27, 2018	EX-4.1	First Supplemental Indenture, dated November 27, 2018, between Corium International, Inc. and U.S. Bank National Association. Exhibit 4.1 CORIUM INTERNATIONAL, INC., AS COMPANY, and U.S. BANK NATIONAL ASSOCIATION, AS TRUSTEE First Supplemental Indenture Dated as of November 27, 2018 to the Indenture Dated as of March 5, 2018 FIRST SUPPLEMENTAL INDENTURE This FIRST SUPPLEMENTAL INDENTURE (this “First Supplemental Indenture”), dated as of November 27, 2018, is by and between Corium International, Inc., a Delaware corporati
November 27, 2018	SC 14D9/A	CORI / Corium International, Inc. SC 14D9/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No. 5) CORIUM INTERNATIONAL, INC. (Name of Subject Company) CORIUM INTERNATIONAL, INC. (Name of Person Filing Statement) Common Stock, par value $0.001 per share (Title of Class of Securi
November 27, 2018	SC TO-T/A	CORI / Corium International, Inc. / Gurnet Merger Sub, Inc. - SC TO-T/A Execution Form Privileged & Confidential UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
November 27, 2018	EX-99.(A)(5)(E)	Press release, dated November 27, 2018 (incorporated by reference to Exhibit (a)(5)(E) to Amendment 3 to the Schedule TO filed with the SEC on November 27, 2018). Exhibit (a)(5)(E) Gurnet Point Capital Completes Tender Offer for Corium International, Transaction Valued in Excess of $500 Million CAMBRIDGE, Mass.
November 15, 2018	SC 14D9/A	CORI / Corium International, Inc. SC 14D9/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No. 4) CORIUM INTERNATIONAL, INC. (Name of Subject Company) CORIUM INTERNATIONAL, INC. (Name of Person Filing Statement) Common Stock, par value $0.001 per share (Title of Class of Securi
November 15, 2018	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): November 9, 2018 Corium International, Inc.
November 13, 2018	SC 14D9/A	CORI / Corium International, Inc. SC 14D9/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No. 3) CORIUM INTERNATIONAL, INC. (Name of Subject Company) CORIUM INTERNATIONAL, INC. (Name of Person Filing Statement) Common Stock, par value $0.001 per share (Title of Class of Securi
November 13, 2018	EX-99.(A)(5)(D)	Class Action Complaint as filed November 6, 2018 (Klein v. Corium International, Inc., et. al., Case No. 4:18-cv-06731-PJH) (incorporated by reference to Exhibit (a)(5)(D) to Amendment No. 2 to the Tender Offer Statement on Schedule TO filed with the SEC on November 13, 2018). Exhibit 99.1(a)(5)(D) Case 3:18-cv-06731 Document 1 Filed 11/06/18 Page 1 of 12 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 TOSTRUD LAW GROUP, P.C. JON A. TOSTRUD 1925 Century Park East. Suite 2100 Los Angeles, CA 90067 Telephone: (310) 278-2600 Facsimile: (310) 278-2640 Email: [email protected] GAINEY McKENNA & EGLESTON THOMAS J. MCKENNA 440 Park Avenue South,
November 13, 2018	SC TO-T/A	CORI / Corium International, Inc. SC TO-T/A SC TO-T/A 1 a18-3714311sctota.htm SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 2) Corium International, Inc. (Name of Subject Company (Issuer)) GURNET MERGER SUB, INC. (Offeror) A Wholly Owned Subsidiary of GURNET HOLDING COMPANY (Parent o
November 13, 2018	EX-99.(A)(5)(C)	Class Action Complaint as filed November 5, 2018 (Kent v. Corium International, Inc., et. al., Case No. 1:18-cv-01744-CFC) (incorporated by reference to Exhibit (a)(5)(C) to Amendment No. 2 to the Tender Offer Statement on Schedule TO filed with the SEC on November 13, 2018). Exhibit 99.(a)(5)(C) Case 1:18-cv-01744-UNA Document 1 Filed 11/05/18 Page 1 of 13 PageID #: 1 IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE MICHAEL KENT, Individually and On Behalf of All Others Similarly Situated, ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) Plaintiff, Case No. v. JURY TRIAL DEMANDED CORIUM INTERNATIONAL, INC., DAVID L. GREENWOOD, ERIC H. BJERKHOLT, BHASKAR CHAUDHURI, RO
November 8, 2018	EX-99.(A)(5)(D)	Instruction Form distributed to Corium’s employees on November 8, 2018. Exhibit (a)(5)(D) INSTRUCTION FORM FOR SHARES OF CORIUM INTERNATIONAL, INC.’S COMMON STOCK HELD AT SOLIUM/RBC In connection with Offer to Purchase All Outstanding Shares of Common Stock of Corium International, Inc. at $12.50 per Share, plus one non-transferable contingent value right for each share, which represents the contractual right to receive $0.50 per Share following approval by the FDA of
November 8, 2018	SC 14D9/A	CORI / Corium International, Inc. SC 14D9/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No. 2) CORIUM INTERNATIONAL, INC. (Name of Subject Company) CORIUM INTERNATIONAL, INC. (Name of Person Filing Statement) Common Stock, par value $0.001 per share (Title of Class of Securi
November 5, 2018	SC 14D9/A	CORI / Corium International, Inc. SC 14D9/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No. 1) CORIUM INTERNATIONAL, INC. (Name of Subject Company) CORIUM INTERNATIONAL, INC. (Name of Person Filing Statement) Common Stock, par value $0.001 per share (Title of Class of Securi
November 5, 2018	EX-99.(A)(5)(D)	Equity Notice distributed to Corium’s employees on November 5, 2018. Exhibit (a)(5)(D) Corium International, Inc. Equity Notice November 5, 2018 You are receiving this notice (this “Notice”) because you hold one or more of the following awards granted or issued under the Corium International, Inc. (the “Company”) 2012 Equity Incentive Plan, 2014 Equity Incentive Plan or 2014 Employee Stock Purchase Plan: · shares of the Company’s Common Stock (“Company Shares”); ·
November 5, 2018	SC TO-T/A	CORI / Corium International, Inc. SC TO-T/A SC TO-T/A 1 a18-3714310sctota.htm SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 1) Corium International, Inc. (Name of Subject Company (Issuer)) GURNET MERGER SUB, INC. (Offeror) A Wholly Owned Subsidiary of GURNET HOLDING COMPANY (Parent o
November 5, 2018	EX-99.(A)(5)(B)	Class Action Complaint as filed November 2, 2018 (Schwartz v. Corium International, Inc., et. al., Case No. 3:18-cv-06670-LHK) (incorporated by reference to Exhibit (a)(5)(B) to Amendment No. 1 to the Tender Offer Statement on Schedule TO filed with the SEC on November 5, 2018). Exhibit (a)(5)(B) Benjamin Heikali (SBN 307466) FARUQI & FARUQI, LLP 10866 Wilshire Boulevard, Suite 1470 Los Angeles, CA 90024 Telephone: (424) 256-2884 Facsimile: (424) 256-2885 E-mail: bheikali@faruqilaw.
November 5, 2018	EX-99.(A)(5)(A)	Class Action Complaint as filed October 29, 2018 (Wang v. Corium International, Inc., et. al., Case No. 4:18-cv-06590-JSW) (incorporated by reference to Exhibit (a)(5)(A) to Amendment No. 1 to the Tender Offer Statement on Schedule TO filed with the SEC on November 5, 2018). Exhibit (a)(5)(A) RACHELE R. BYRD (SBN 190634) MARISA C. LIVESAY (SBN 223247) BRITTANY N. DEJONG (SBN 258766) WOLF HALDENSTEIN ADLER FREEMAN & HERZ LLP 750 B Street, Suite 2770 San Diego, CA 92101 Telephone: (619) 239-4599 Facsimile: (619) 234-4599 [email protected] [email protected] [email protected] Attorneys for Plaintiff [Additional Counsel on Signature Page] UNITED STATES DISTRICT COURT NORTHERN
October 26, 2018	SC 14D9	CORI / Corium International, Inc. SC 14D9 Use these links to rapidly review the document TABLE OF CONTENTS Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
October 26, 2018	EX-99.(D)(2)	Commitment Letter, dated October 11, 2018, among Gurnet Point L.P. and Gurnet Holding Company (incorporated by reference to Exhibit (d)(2) to the Schedule TO). Exhibit (d)(2) Gurnet Point L.P. 55 Cambridge Parkway, Suite 401 Cambridge, MA 02142 October 11, 2018 Gurnet Holding Company 55 Cambridge Parkway, Suite 401 Cambridge, MA 02142 Re: Funding Commitment Ladies and Gentlemen: Reference is made to the Agreement and Plan of Merger, dated as of the date hereof (the “Merger Agreement”), by and among Gurnet Holding Company, a Delaware corporation (“Parent”
October 26, 2018	EX-99.(D)(6)	Transition Bonus Plan (incorporated by reference to Exhibit (d)(6) to the Schedule TO). Exhibit (d)(6) FINAL FORM Corium International, Inc. TRANSITION BONUS PLAN This document sets forth the terms of the Corium International, Inc., Transition Bonus Plan (the “Plan”). The purpose of the Plan is to advance the interests of Corium International, Inc., and any Affiliate thereof (collectively, “Corium”) by motivating and retaining the employees of Corium to contribute to the success and
October 26, 2018	EX-99.(A)(1)(C)	Notice of Guaranteed Delivery (incorporated by reference to Exhibit (a)(1)(C) to the Schedule TO). QuickLinks - Click here to rapidly navigate through this document Exhibit (a)(1)(C) NOTICE OF GUARANTEED DELIVERY to Tender Shares of Common Stock of CORIUM INTERNATIONAL, INC.
October 26, 2018	EX-99.(A)(1)(D)	Letter to Brokers, Dealers, Commercial Banks, Trust Companies and Other Nominees (incorporated by reference to Exhibit (a)(1)(D) to the Schedule TO). QuickLinks - Click here to rapidly navigate through this document Exhibit (a)(1)(D) Offer to Purchase All Outstanding Shares of Common Stock of CORIUM INTERNATIONAL, INC.
October 26, 2018	EX-99.(D)(3)	Confidentiality Agreement, effective as of May 17, 2018, between Corium International, Inc. and Gurnet Point Capital, LLC (incorporated by reference to Exhibit (d)(3) to the Schedule TO). Exhibit (d)(3) May 17, 2018 CONFIDENTIAL Gurnet Point Capital, LLC 55 Cambridge Parkway, Suite 401 Cambridge, MA 02142 Ladies and Gentlemen: In connection with the consideration of a possible negotiated transaction between Gurnet Point Capital, LLC (“GPC”) and Corium International, Inc.
October 26, 2018	EX-99.(D)(7)	Press Release of Gurnet, announcing the launch of the Offer, dated October 26, 2018 (incorporated by reference to Exhibit (d)(7) to the Schedule TO). Exhibit (d)(7) Gurnet Point Commences Cash Tender Offer for All Outstanding Shares of Corium International, Inc.
October 26, 2018	EX-99.(A)(1)(E)	Letter to Clients for use by Brokers, Dealers, Commercial Banks, Trust Companies and Other Nominees (incorporated by reference to Exhibit (a)(1)(E) to the Schedule TO). QuickLinks - Click here to rapidly navigate through this document Exhibit (a)(1)(E) Offer to Purchase All Outstanding Shares of Common Stock of CORIUM INTERNATIONAL, INC.
October 26, 2018	EX-99.(A)(1)(F)	Summary Advertisement as published in the New York Times, dated October 26, 2018 (incorporated by reference to Exhibit (a)(1)(F) to the Schedule TO). QuickLinks - Click here to rapidly navigate through this document Exhibit (a)(1)(F) This announcement is neither an offer to purchase nor a solicitation of an offer to sell Shares (as defined below).
October 26, 2018	EX-99.(A)(1)(A)	Offer to Purchase, dated October 26, 2018 (incorporated by reference to Exhibit (a)(1)(A) to the Tender Offer Statement on Schedule TO filed with the SEC by Gurnet Holding Company and Gurnet Merger Sub, Inc. on October 26, 2018 Table of Contents Exhibit (a)(1)(A) Offer To Purchase All Outstanding Shares of Common Stock of CORIUM INTERNATIONAL, INC.
October 26, 2018	SC TO-T	CORI / Corium International, Inc. SC TO-T SC TO-T 1 a2236974zscto-t.htm SC TO-T QuickLinks - Click here to rapidly navigate through this document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 Corium International, Inc. (Name of Subject Company (Issuer)) GURNET MERGER SUB, INC. (Offeror) A Wholly Owned Subs
October 26, 2018	EX-99.(A)(1)(B)	Letter of Transmittal (incorporated by reference to Exhibit (a)(1)(B) to the Schedule TO). QuickLinks - Click here to rapidly navigate through this document Exhibit (a)(1)(B) LETTER OF TRANSMITTAL to Tender Shares of Common Stock of CORIUM INTERNATIONAL, INC.
October 22, 2018	EX-99.2	Exhibit 99.2 - Joint Filers’ Signatures Exhibit 99.2 Exhibit 99.2 - Joint Filers’ Signatures Designated Filer: Gurnet Holding Company Issuer & Ticker Symbol: Corium International, Inc. (CORI) Date of Event Requiring Statement: October 11, 2018 GURNET HOLDING COMPANY By: /s/ James B. Singleton Name: James B. Singleton Title: Secretary Date: October 22, 2018 GURNET MERGER SUB, INC. By: /s/ James B. Singleton Name: James B. Singleton Title
October 22, 2018	EX-99.1	Exhibit 99.1 - Joint Filer Information Exhibit 99.1 Exhibit 99.1 - Joint Filer Information Designated Filer: Gurnet Holding Company Issuer & Ticker Symbol: Corium International, Inc. (CORI) Date of Event Requiring Statement: October 11, 2018 Joint Filers: 1. Name: Gurnet Holding Company Address: c/o Waypoint International GP LLC 55 Cambridge Parkway, Suite 401 Cambridge, MA 02142 2. Name: Gurnet Merger Sub, Inc. Address: c/o Waypoint I
October 22, 2018	EX-2	AGREEMENT AND PLAN OF MERGER CORIUM INTERNATIONAL, INC., GURNET HOLDING COMPANY, GURNET MERGER SUB, INC. OCTOBER 11, 2018 Exhibit 2 AGREEMENT AND PLAN OF MERGER among CORIUM INTERNATIONAL, INC., GURNET HOLDING COMPANY, and GURNET MERGER SUB, INC. OCTOBER 11, 2018 TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS 2 Section 1.01. Definitions 2 Section 1.02. Other Definitional and Interpretative Provisions 12 ARTICLE 2 THE OFFER AND THE MERGER 13 Section 2.01. The Offer 13 Section 2.02. Company Actions 16 Section 2.03. The C
October 22, 2018	EX-1	JOINT FILING AGREEMENT Exhibit 1 JOINT FILING AGREEMENT Pursuant to Rule 13d-1(k) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree to the joint filing of this Statement on Schedule 13D including any amendments thereto.
October 22, 2018	SC 13D	CORI / Corium International, Inc. / Gurnet Holding Co - SC 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 Corium International, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 21887L107 (CUSIP Number) Peter D. Staple Chief Executive Officer 235 Constitution Drive Menlo Park, California 94025 (650) 298-8255 (Name, Address and Teleph
October 22, 2018	EX-3	TENDER AND SUPPORT AGREEMENT Exhibit 3 TENDER AND SUPPORT AGREEMENT This Tender and Support Agreement (this “Agreement”) is made and entered into as of October 11, 2018, by and among Gurnet Holding Company, a Delaware corporation (“Parent”), Gurnet Merger Sub, Inc.
October 16, 2018	SC 13G/A	CORI / Corium International, Inc. / PERCEPTIVE ADVISORS LLC - AMENDMENT NO. 3 TO SCHEDULE 13G Passive Investment Amendment No. 3 to Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* Corium International, Inc. (Name of Issuer) Common stock, par value $0.001 per share (Title of Class of Securities) 21887L 10 7 (CUSIP Number) October 12, 2018 (Date of Event Which Requires Filing of this Statement) Check
October 15, 2018	SC 13G/A	CORI / Corium International, Inc. / Broadfin Capital, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.
October 11, 2018	EX-99.1	Email to Employees, dated October 11, 2018. Exhibit 99.1 A Message from Chief Executive Officer, Peter Staple Today we announced that our Company has entered into a merger agreement with Gurnet Point Capital, a healthcare-focused investment firm that acquires life science companies, invests in their operations, and builds them into larger businesses. While it will take several steps to complete this transaction over the coming months, I wan
October 11, 2018	EX-99.3	Employee Q&A, dated October 11, 2018. Exhibit 99.3 EMPLOYEE Q&A GENERAL Q1 Will this result in the elimination of any jobs? A1 We expect our management and teams will remain the same, and we’ll have financial resources to support our business plan. Q2 Will there be changes to the programs/products we are currently working on? A2 We expect to continue to grow our commercial operations and to pursue development of our product pipeline.
October 11, 2018	EX-99.2	Employee Talking Points, dated October 11, 2018. Exhibit 99.2 Employee Talking Points · We announced this afternoon that Corium has entered into an agreement with Gurnet Point Capital, providing for Gurnet Point to purchase all of the shares of Corium’s common stock. Gurnet Point is a healthcare-focused investment firm that specializes in acquiring life science companies, investing in their operations, and building them into larger enterprises.
October 11, 2018	SC14D9C	CORI / Corium International, Inc. SC14D9C UNITED STATES
October 11, 2018	EX-2.3	Tender and Support Agreement, dated October 11, 2018, among Gurnet Holding Company, Gurnet Merger Sub, Inc. and Essex Woodlands Health Ventures Fund VII, L.P. (incorporated by reference to Exhibit 2.3 to the Current Report on Form 8-K filed with the SEC by Corium International, Inc. on October 11, 2018). Exhibit 2.3 TENDER AND SUPPORT AGREEMENT This Tender and Support Agreement (this “Agreement”) is made and entered into as of October 11, 2018, by and among Gurnet Holding Company, a Delaware corporation (“Parent”), Gurnet Merger Sub, Inc., a Delaware corporation and indirect wholly-owned subsidiary of Parent (“Merger Sub”), and each Person set forth in Schedule A hereto (each, a “Stockholder”). WH
October 11, 2018	EX-2.2	Form of Contingent Value Rights Agreement, between Gurnet Holding Company and Continental Stock Transfer & Trust Company (incorporated by reference to Exhibit 2.2 to the Current Report on Form 8-K filed with the SEC by Corium International, Inc. on October 11, 2018). Exhibit 2.2 CONTINGENT VALUE RIGHTS AGREEMENT THIS CONTINGENT VALUE RIGHTS AGREEMENT (this “Agreement”) is entered into as of October 11, 2018, by and between Gurnet Holding Company, a Delaware corporation (“Parent”) and Continental Stock Transfer & Trust Company, a New York Corporation, as Rights Agent; provided that this Agreement shall be contingent upon, and only become effective upon, the Eff
October 11, 2018	EX-99.1	Corium Announces Agreement for Gurnet Point Capital to Purchase All Outstanding Shares Exhibit 99.1 Corium Announces Agreement for Gurnet Point Capital to Purchase All Outstanding Shares Total Transaction Valued in Excess of $500 Million, Representing a 50% Premium Gurnet Point Capital to Expand Operations While Focusing on the Approval and Commercialization of Corium’s Corplex Donepezil MENLO PARK, Calif., October 11, 2018 (GLOBE NEWSWIRE) — Corium International, Inc. (Nasdaq: CORI
October 11, 2018	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): October 11, 2018 Corium International, Inc.
October 11, 2018	EX-2.1	Agreement and Plan of Merger, among Corium International, Inc., Gurnet Holding Company and Gurnet Merger Sub, Inc., dated as of October 11, 2018 (incorporated by reference to Exhibit 2.1 to the Current Report on Form 8-K filed with the SEC by Corium International, Inc. on October 11, 2018). EX-2.1 2 a18-366171ex2d1.htm EX-2.1 Exhibit 2.1 AGREEMENT AND PLAN OF MERGER among CORIUM INTERNATIONAL, INC., GURNET HOLDING COMPANY, and GURNET MERGER SUB, INC. OCTOBER 11, 2018 TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS 2 Section 1.01. Definitions 2 Section 1.02. Other Definitional and Interpretative Provisions 12 ARTICLE 2 THE OFFER AND THE MERGER 13 Section 2.01. The Offer 13 Section 2.02.
August 10, 2018	10-Q	CORI / Corium International, Inc. 10-Q (Quarterly Report) 10-Q 1 cori-20180630x10q.htm 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2018 OR ☐Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to . Com
August 9, 2018	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): August 9, 2018 Corium International, Inc.
August 9, 2018	EX-99.1	CORIUM INTERNATIONAL, INC. CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (In thousands, except share and per share data) Exhibit 99.1 Corium Reports Third Quarter Fiscal 2018 Financial Results and Corporate Highlights MENLO PARK, Calif., August 9, 2018 (GLOBE NEWSWIRE) – Corium International, Inc. (Nasdaq: CORI), a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal products, today announced unaudited financial results for the third fiscal
July 16, 2018	CORRESP	CORI / Corium International, Inc. CORRESP CORIUM INTERNATIONAL, Inc. 235 Constitution Drive Menlo Park, California 94025 July 16, 2018 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Healthcare & Insurance 100 F Street, N.E. Washington, DC 20549 Attention:Jeffrey Gabor Re: Corium International, Inc. Registration Statement on Form S-3 (File No. 333-225497) filed June 7, 2018. Requested D
July 11, 2018	CORRESP	CORI / Corium International, Inc. CORRESP July 11, 2018 VIA EDGAR Jeffrey Gabor Office of Healthcare and Insurance U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: Corium International, Inc. Registration Statement on Form S-3 Filed June 7, 2018 File No. 333-225497 Dear Mr. Gabor: On behalf of Corium International, Inc. (the “Company”), this letter sets forth the response to the comment from the staff (
June 29, 2018	CORRESP	CORI / Corium International, Inc. CORRESP June 29, 2018 VIA EDGAR Jeffrey Gabor Office of Healthcare and Insurance U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: Corium International, Inc. Registration Statement on Form S-3 Filed June 7, 2018 File No. 333-225497 Dear Mr. Gabor: On behalf of Corium International, Inc. (the “Company”), this letter sets forth the response to the comment from the staff (
June 7, 2018	S-3	CORI / Corium International, Inc. S-3 Table of Contents As filed with the Securities and Exchange Commission on June 7, 2018 Registration No.
June 7, 2018	EX-4.4	Form of Indenture Exhibit 4.4 CORIUM INTERNATIONAL, INC. And , as Trustee INDENTURE Dated as of , TABLE OF CONTENTS ARTICLE 1 - DEFINITIONS AND INCORPORATION BY REFERENCE 1 1.1 DEFINITIONS 1 1.2. OTHER DEFINITIONS 4 1.3. INCORPORATION BY REFERENCE OF TRUST INDENTURE ACT 5 1.4. RULES OF CONSTRUCTION 5 ARTICLE 2 - THE SECURITIES 5 2.1. ISSUABLE IN SERIES 5 2.2. ESTABLISHMENT OF TERMS OF SERIES OF SECURITIES 6 2.3. EX
June 7, 2018	EX-4.3	Form of Debt Security Exhibit 4.3 FORM OF DEBT SECURITY [Face of Security] CORIUM INTERNATIONAL, INC. [If applicable, insert—FOR PURPOSES OF THE ORIGINAL ISSUE DISCOUNT PROVISIONS OF THE INTERNAL REVENUE CODE OF 1986, THE ISSUE PRICE OF THIS SECURITY IS % OF ITS PRINCIPAL AMOUNT AT STATED MATURITY SET FORTH BELOW (ITS “PRINCIPAL AMOUNT”), THE AMOUNT OF ORIGINAL ISSUE DISCOUNT IS % OF ITS PRINCIPAL AMOUNT, THE YIELD TO
June 7, 2018	EX-12.1	Statement of Computation of Ratio of Earnings to Fixed Charges Exhibit 12.1 CORIUM INTERNATIONAL, INC. Ratio of Earnings to Fixed Charges The following table shows our ratio of earnings to fixed charges for the periods indicated: Year Ended September 30, Six Months Ended March 31, 2013 2014 2015 2016 2017 2018 Earnings (loss): Pre-tax income (loss) from continuing operations before adjustment for income (loss) from equity investees $ (13,876) $ (9,911) $ (28,
May 14, 2018	10-Q	CORI / Corium International, Inc. 10-Q (Quarterly Report) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2018 OR ☐Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to . Commission File Number: 001-36375 Co
May 14, 2018	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): May 14, 2018 Corium International, Inc.
May 14, 2018	EX-99.1	CORIUM INTERNATIONAL, INC. CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (In thousands, except share and per share data) Exhibit 99.1 Corium Reports Second Quarter Fiscal 2018 Financial Results and Corporate Highlights MENLO PARK, Calif., May 14, 2018 (GLOBE NEWSWIRE) – Corium International, Inc. (Nasdaq: CORI), a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal products, today announced unaudited financial results for the second fiscal
March 27, 2018	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): March 27, 2018 Corium International, Inc.
March 27, 2018	EX-99.1	Corium Investor Update 17th Annual Needham Healthcare Conference Nasdaq: CORI March 2018 Corium Exhibit 99.1 Corium Investor Update 17th Annual Needham Healthcare Conference Nasdaq: CORI March 2018 Corium Forward-looking Statements This presentation and the accompanying oral presentation contain “forward-looking” statements that are based on our management’s beliefs and assumptions and on information currently available to management. Forward-looking statements include all statements other t
March 20, 2018	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): March 20, 2018 Corium International, Inc.
March 16, 2018	8-K	Unregistered Sales of Equity Securities, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): March 16, 2018 Corium International, Inc.
March 15, 2018	EX-99.1	JOINT FILING AGREEMENT EX-99.1 2 tv487836ex99-1.htm JOINT FILING AGREEMENT Exhibit 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that statements on Schedules 13G and/or 13D and Forms 3, 4 and 5 with respect to the shares of common stock of Corium International Inc. and any amendments thereto signed by each of the undersigned shall be filed on behalf of each of the undersigned pursuant to and in accordance wit
March 15, 2018	SC 13G	CORI / Corium International, Inc. / Ridgeback Capital Investments L.P. - SCHEDULE 13G Passive Investment SC 13G 1 tv487836sc13g.htm SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Amendment No. ) UNDER THE SECURITIES EXCHANGE ACT OF 19341 Corium International, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 21887L107 (CUSIP Number) March 5, 2018 (Date of Event Which Requires Filing of this Statement) Check
March 5, 2018	8-K	Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): March 5, 2018 Corium International, Inc.
March 5, 2018	EX-4.1	Indenture, dated as of March 5, 2018, between Corium and U.S. Bank National Association (including the form of 5.00% Convertible Senior Notes due 2025). Exhibit 4.1 CORIUM INTERNATIONAL, INC. and U.S. BANK NATIONAL ASSOCIATION as Trustee INDENTURE Dated as of March 5, 2018 5.00% Convertible Senior Notes due 2025 TABLE OF CONTENTS Page Article 1. Definitions; Rules of Construction 1 Section 1.01. Definitions. 1 Section 1.02. Other Definitions. 11 Section 1.03. Rules of Construction. 12 Article 2. The Notes 12 Section 2.01. Form, Dating and Denomina
March 5, 2018	SC 13G	CORI / Corium International, Inc. / RTW INVESTMENTS, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.
March 5, 2018	EX-1	Joint Filing Statement Pursuant to Rule 13d-1(k)(1) Exhibit 1 Joint Filing Statement Pursuant to Rule 13d-1(k)(1) The undersigned hereby consent and agree to the joint filing of Schedule 13G under the Securities Exchange Act of 1934, as amended, with respect to the Common stock, $0.
March 1, 2018	EX-99.1	### EX-99.1 2 ex-99d1.htm EX-99.1 Exhibit 99.1 Corium Prices Offering of $100 Million of 5% Convertible Senior Notes MENLO PARK, Calif., March 1, 2018 (GLOBE NEWSWIRE) – Corium International, Inc. (Nasdaq: CORI), a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal products, today announced the pricing of its offering of $1
March 1, 2018	8-K	Financial Statements and Exhibits, Other Events coriCurrentFolio8k UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8?K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): March 1, 2018 Corium International, Inc.
February 28, 2018	EX-99.1	### coriEx991 Exhibit 99.1 Corium Announces Proposed Offering of $100 Million of Convertible Senior Notes; Receives FDA Feedback on Pilot Bioequivalence Study MENLO PARK, Calif., February 28, 2018 (GLOBE NEWSWIRE) ? Corium International, Inc. (Nasdaq: CORI), a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal products, tod
February 28, 2018	8-K	Financial Statements and Exhibits, Other Events coriCurrent Folio8K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): February 28, 2018 Corium International, Inc.
February 28, 2018	EX-99.2	Corium Investor Update EX-99.2 3 ex-99d2.htm EX-99.2 Exhibit 99.2 Corium Investor Update Forward-looking Statements This presentation and the accompanying oral presentation contain “forward-looking” statements that are based on our management’s beliefs and assumptions and on information currently available to management. Forward-looking statements include all statements other than statements of historical fact contained
February 14, 2018	EX-1	Joint Filing Statement Pursuant to Rule 13d-1(k)(1) Exhibit 1 Joint Filing Statement Pursuant to Rule 13d-1(k)(1) The undersigned hereby consent and agree to the joint filing of Schedule 13G Amendment No.
February 14, 2018	SC 13G/A	CORI / Corium International, Inc. / RTW INVESTMENTS, LLC - 3G/A (Passive Investment) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.
February 14, 2018	SC 13G/A	CORI / Corium International, Inc. / PERCEPTIVE ADVISORS LLC - AMENDMENT NO. 2 TO SCHEDULE 13G Passive Investment Amendment No. 2 to Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Corium International, Inc. (Name of Issuer) Common stock, par value $0.001 per share (Title of Class of Securities) 21887L 10 7 (CUSIP Number) December 31, 2017 (Date of Event Which Requires Filing of this Statement) Check
February 14, 2018	SC 13G/A	CORI / Corium International, Inc. / SENZAR ASSET MANAGEMENT, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.
February 13, 2018	SC 13G/A	CORI / Corium International, Inc. / Broadfin Capital, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.
February 12, 2018	S-8	CORI / Corium International, Inc. S-8 coriCurrentFolioS8 As filed with the Securities and Exchange Commission on February 12, 2018 Registration No.
February 12, 2018	10-Q	CORI / Corium International, Inc. 10-Q (Quarterly Report) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended December 31, 2017 OR ☐Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to . Commission File Number: 001-36375
February 8, 2018	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition cori8K20180207ER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): February 8, 2018 Corium International, Inc.
February 8, 2018	EX-99.1	CORIUM INTERNATIONAL, INC. CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (In thousands, except share and per share data) coriEx991 Exhibit 99.1 Corium Reports First Quarter Fiscal 2018 Financial Results and Corporate Highlights MENLO PARK, Calif., February 8, 2018 (GLOBE NEWSWIRE) ? Corium International, Inc. (Nasdaq: CORI), a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal products, today announced unaudited financial results for the
January 24, 2018	DEF 14A	CORI / Corium International, Inc. DEF 14A coriCurrentFolioProxy Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.
December 29, 2017	EX-10.10	Form of Change in Control and Severance Agreement (Other Executive) Exhibit 10.10 CHANGE IN CONTROL AND SEVERANCE AGREEMENT This Change in Control and Severance Agreement (the “Agreement”) is entered into by and between (the “Executive”) and Corium International, Inc., a Delaware corporation (the “Company”), on , 2017, and is effective as of , 20 (the “Effective Date”). 1. Term of Agreement. Except to the extent renewed as set forth in this Section 1, this Agreeme
December 29, 2017	EX-10.9	Form of CEO Change in Control and Severance Agreement (CEO) Exhibit 10.9 CHANGE IN CONTROL AND SEVERANCE AGREEMENT This Change in Control and Severance Agreement (the ?Agreement?) is entered into by and between (the ?Executive?) and Corium International, Inc., a Delaware corporation (the ?Company?), on , 20, and is effective as of , 20 (the ?Effective Date?). 1.Term of Agreement. Except to the extent renewed as set forth in this Section 1, this Agreement s
December 29, 2017	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10‑K coriCurrent folio10K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
November 16, 2017	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition cori8k20171116ER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): November 16, 2017 Corium International, Inc.
November 16, 2017	EX-99.1	CORIUM INTERNATIONAL, INC. CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (In thousands, except share and per share data) coriEx991 Exhibit 99.1 Corium Reports Fourth Quarter and Fiscal Year 2017 Financial Results and Corporate Highlights MENLO PARK, Calif., November 16, 2017 (GLOBE NEWSWIRE) ? Corium International, Inc. (Nasdaq: CORI), a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal products, today announced unaudited financial resul
August 11, 2017	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q coriCurrent folio10Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
August 11, 2017	EX-10.1	Supply Agreement by and between the Registrant and The Procter & Gamble Manufacturing Company, dated as of May 1, 2017, as amended May 5, 2017 Exhibit 10.1 [*] Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. SUPPLY AGREEMENT This is an agreement (“AGREEMENT”), made and entered into between the BUYER and SELLER (“PARTY,” collectively “PARTIES”). 1 PART
August 3, 2017	EX-99.1	CORIUM INTERNATIONAL, INC. CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (In thousands, except share and per share data) coriEx991 Exhibit 99.1 FOR IMMEDIATE RELEASE Corium Reports Recent Corporate Highlights and Financial Results for Third Quarter Fiscal 2017 MENLO PARK, Calif., August 3, 2017 (GLOBE NEWSWIRE) – Corium International, Inc. (Nasdaq: CORI), a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal products, today announced unaud
August 3, 2017	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition cori8k20170803ER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): August 3, 2017 Corium International, Inc.
July 14, 2017	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers cori8K20170712 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8?K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): July 12, 2017 Corium International, Inc.
May 25, 2017	EX-1.1	5,600,000 Shares of Common Stock Corium International, Inc. UNDERWRITING AGREEMENT coriEx11 Exhibit 1.1 5,600,000 Shares of Common Stock Corium International, Inc. UNDERWRITING AGREEMENT May 25, 2017 JEFFERIES LLC As Representative of the several Underwriters c/o JEFFERIES LLC 520 Madison Avenue New York, NY 10022 Ladies and Gentlemen: Introductory. Corium International, Inc., a Delaware corporation (the ?Company?), proposes to issue and sell to the several underwriters named in
May 25, 2017	EX-99.1	May 25, 2017 coriEx991 Exhibit 99.1 May 25, 2017 Corium Prices Follow-On Offering of Common Stock MENLO PARK, Calif., May 25, 2017 (GLOBE NEWSWIRE) - Corium International, Inc. (Nasdaq:CORI), a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal products, today announced the pricing of its underwritten public offering of 5,600,000 sh
May 25, 2017	8-K	Corium International 8-K (Current Report/Significant Event) coriCurrentFolio8K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): May 25, 2017 Corium International, Inc.
May 25, 2017	424B5	5,600,000 Shares Corium International, Inc. Common Stock coriProsSuppMay2017 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No.
May 25, 2017	EX-24	Information Regarding Joint Filers Exhibit 24 Information Regarding Joint Filers Designated Filer of Form 3: Perceptive Advisors LLC Date of Earliest Transaction Required to be Reported: 05/19/17 Issuer Name and Ticker Symbol: Corium International, Inc.
May 25, 2017	SC 13G/A	CORI / Corium International, Inc. / Broadfin Capital, LLC Passive Investment SC 13G/A 1 d750189013ga.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4)* Corium International, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 21887L107 (CUSIP Number) May 25, 2017 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rul
May 24, 2017	424B5	SUBJECT TO COMPLETION, DATED MAY 24, 2017 coriProsSuppMay2017 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No.
May 23, 2017	SC 13G/A	CORI / Corium International, Inc. / PERCEPTIVE ADVISORS LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A (Amendment No. 1) Under the Securities Exchange Act of 1934 Corium International, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 21887L 10 7 (CUSIP Number) May 19, 2017 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which thi
May 12, 2017	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2017 OR ☐Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to . Commission File Number: 001-36375 Co
May 11, 2017	EX-99.2	Corplex Donepezil® Pilot Bioequivalence Study Preliminary Results May 11, 2017 coriEx992 Exhibit 99.2 Corplex Donepezil® Pilot Bioequivalence Study Preliminary Results May 11, 2017 Forward-looking Statements This presentation and the accompanying oral presentation contain “forward-looking” statements that are based on our management’s beliefs and assumptions and on information currently available to management. Forward-looking statements include all statements other than sta
May 11, 2017	8-K	Regulation FD Disclosure, Financial Statements and Exhibits cori8k20170511Alternate UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): May 11, 2017 Corium International, Inc.
May 11, 2017	EX-99.1	### coriEx991 Exhibit 99.1 Corium Reports Positive Preliminary Results in Alzheimer?s Clinical Study Once-Weekly Corplex? Donepezil Patch Achieves Bioequivalence to Aricept? MENLO PARK, Calif., May 11, 2017 (GLOBE NEWSWIRE) - Corium International, Inc. (Nasdaq: CORI), a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal pro
May 11, 2017	EX-99.1	CORIUM INTERNATIONAL, INC. CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (In thousands, except share and per share data) Exhibit 99.1 Corium Reports Second Quarter Fiscal 2017 Financial Results and Recent Corporate Highlights MENLO PARK, Calif., May 11, 2017 (GLOBE NEWSWIRE) – Corium International, Inc. (Nasdaq: CORI), a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal products, today announced unaudited financial results for the second
May 11, 2017	8-K	Corium International 8-K (Current Report/Significant Event) cori8K20170511 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): May 11, 2017 Corium International, Inc.
May 5, 2017	SC 13G	CORI / Corium International, Inc. / RTW INVESTMENTS, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.
May 1, 2017	8-K	Entry into a Material Definitive Agreement 8-K 1 f8-k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): April 25, 2017 Corium International, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36375 38-3230774 (State or other jurisdiction of incorpo
March 9, 2017	8-K	Corium International 8-K (Current Report/Significant Event) coriCurrentFolio8K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): March 9, 2017 Corium International, Inc.
February 22, 2017	CORRESP	Corium International ESP coriCurrent folioCORRESP February 22, 2017 VIA EDGAR Suzanne Hayes, Assistant Director Office of Healthcare and Insurance U.
February 15, 2017	SC 13G	CORI / Corium International, Inc. / PERCEPTIVE ADVISORS LLC - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Corium International, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 21887L 10 7 (CUSIP Number) February 2, 2017 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is fi
February 14, 2017	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended December 31, 2016 OR ☐Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to . Commission File Number: 001-36375
February 13, 2017	S-8	Corium International S-8 coriS820170214 As filed with the Securities and Exchange Commission on February 14, 2017 Registration No.
February 13, 2017	EX-99.1	CORIUM INTERNATIONAL, INC. CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (In thousands, except share and per share data) coriEx991 Exhibit 99.1 Corium Reports First Quarter Fiscal 2017 Financial Results MENLO PARK, Calif., February 13, 2017 (GLOBE NEWSWIRE) - Corium International, Inc. (Nasdaq: CORI), a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal products, today announced unaudited financial results for the first fiscal quarter end
February 13, 2017	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 cori-20170213x8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): February 13, 2017 Corium International, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36375 38-3230774 (State or other jurisdic
February 13, 2017	SC 13G/A	CORI / Corium International, Inc. / SENZAR ASSET MANAGEMENT, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.
February 10, 2017	SC 13G/A	CORI / Corium International, Inc. / Broadfin Capital, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.
February 2, 2017	EX-1.1	6,666,667 Shares of Common Stock Corium International, Inc. UNDERWRITING AGREEMENT coriEx11 Exhibit 1.1 6,666,667 Shares of Common Stock Corium International, Inc. UNDERWRITING AGREEMENT February 1, 2017 Cantor Fitzgerald & Co. As Representative of the several Underwriters c/o Cantor Fitzgerald & Co. 499 Park Avenue New York, NY 10022 Ladies and Gentlemen: Introductory. Corium International, Inc., a Delaware corporation (the ?Company?), proposes to issue and sell to the several
February 2, 2017	EX-99.1	2, 2017 EX-99.1 6 cori-20170201ex991b79393.htm EX-99.1 Exhibit 99.1 February 2, 2017 Corium Prices Follow-On Offering of Common Stock MENLO PARK, Calif., Feb. 2, 2017 (GLOBE NEWSWIRE) - Corium International, Inc. (Nasdaq:CORI), a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal products, today announced the pricing of its und
February 2, 2017	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): February 1, 2017 Corium International, Inc.
February 2, 2017	424B5	6,666,667 Shares Corium International, Inc. Common Stock coriCurrentFolio424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No.
February 1, 2017	424B5	SUBJECT TO COMPLETION, DATED FEBRUARY 1, 2017 coriCurrentFolio424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No.
January 20, 2017	EX-10.1	Confidential Treatment Requested EX-10.1 2 cori-20170113ex101a858cb.htm EX-10.1 Exhibit 10.1 [*] Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. AMENDMENT This first amendment ("AMENDMENT #1") to the Restated Supply Agreement, dated June 30, 2
January 20, 2017	8-K	Corium International 8-K (Current Report/Significant Event) coriCurrentFolio8K20170113 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): January 13, 2017 Corium International, Inc.
January 13, 2017	DEF 14A	Corium International DEF 14A coriCurrentFolioProxy Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
January 9, 2017	8-K	Corium International 8-K (Current Report/Significant Event) coriCurrentFolio8-K20170109 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8?K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): January 9, 2017 Corium International, Inc.
January 9, 2017	EX-99.1	Corium Investor Update January 2017 coriEx991 Exhibit 99.1 Corium Investor Update January 2017 Forward-looking Statements This presentation and the accompanying oral presentation contain ?forward-looking? statements that are based on our management?s beliefs and assumptions and on information currently available to management. Forward-looking statements include all statements other than statements of historical fact contained in thi
December 20, 2016	EX-10.23	Amendment Agreement No. 2 to Amended and Restated Term Loan Agreement by and among the Registrant and certain entities affiliated with CRG, dated December 19, 2016. Exhibit 10.23 AMENDMENT AGREEMENT No. 2 THIS AMENDMENT AGREEMENT No. 2 (this ?Amendment?), dated as of December 19, 2016, is made among Corium International, Inc., a Delaware corporation (the ?Borrower?), the Lenders listed on the signature pages hereof under the heading ?LENDERS? (each a ?Lender? and, collectively, the ?Lenders?), and CRG Servicing LLC, as administrative agent for the Lenders (th
December 20, 2016	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10‑K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10‑K ☒ Annual Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended September 30, 2016 OR ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to . Commission File Number: 001‑36375 Cori
November 21, 2016	8-K	Corium International 8-K (Current Report/Significant Event) coriCurrentFolio8K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): November 21, 2016 Corium International, Inc.
November 21, 2016	EX-99.1	CORIUM INTERNATIONAL, INC. Condensed Statements of Operations and Comprehensive Loss (unaudited, in thousands, except share and per share data) coriEx991 Exhibit 99.1 Corium Reports Fourth Quarter and Fiscal Year 2016 Financial Results and Recent Corporate Highlights MENLO PARK, Calif., November 21, 2016 (GLOBE NEWSWIRE) - Corium International, Inc. (Nasdaq: CORI), a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal products, today announced unaudited financia
August 12, 2016	EX-10.1	AMENDMENT TO SEVERANCE BENEFITS LETTER AGREEMENT EX-10.1 2 cori-20160630ex10168166c.htm EX-10.1 Exhibit 10.1 AMENDMENT TO SEVERANCE BENEFITS LETTER AGREEMENT This Amendment to the Severance Benefits Letter Agreement (this “Amendment”) is made and entered into as of August 11, 2016 by and among Parminder Singh (“Executive”) and Corium International, Inc., a Delaware corporation (the “Company”). RECITALS A. The Company and Executive are parties to
August 12, 2016	EX-10.1	AMENDMENT TO SEVERANCE BENEFITS LETTER AGREEMENT EX-10.1 2 cori-20160630ex10168166c.htm EX-10.1 Exhibit 10.1 AMENDMENT TO SEVERANCE BENEFITS LETTER AGREEMENT This Amendment to the Severance Benefits Letter Agreement (this “Amendment”) is made and entered into as of August 11, 2016 by and among Parminder Singh (“Executive”) and Corium International, Inc., a Delaware corporation (the “Company”). RECITALS A. The Company and Executive are parties to
August 12, 2016	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q 10-Q 1 cori-20160630x10q.htm 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2016 OR ☐Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to . Com
August 4, 2016	EX-99.1	# # # coriEx991 Exhibit 99.1 Corium Reports Third Quarter Fiscal 2016 Financial Results and Recent Corporate Highlights MENLO PARK, Calif., August 4, 2016 (GLOBE NEWSWIRE) - Corium International, Inc. (Nasdaq: CORI), a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal products, today announced unaudited financial results for
August 4, 2016	8-K	Corium International 8-K (Current Report/Significant Event) coriCurrentFolio8K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): July 29, 2016 Corium International, Inc.
June 15, 2016	8-K	Costs Associated with Exit or Disposal Activities 8-K 1 cori-20160614x8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): June 14, 2016 Corium International, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36375 38-3230774 (State or other jurisdiction
May 13, 2016	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2016 OR ☐Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to . Commission File Number: 001-36375 Co
May 13, 2016	EX-10.2	Lease Amendment #1, by and between the Registrant and 4741 Talon Court L.L.C., dated May 10, 2016. Exhibit 10.2 LEASE AMENDMENT #1 THIS AMENDMENT TO LEASE (?Amendment?) is made this 10th day of May, 2016 between 4741 Talon Court, L.L.C., a Michigan limited liability company, of One Riverfront Plaza, 55 Campau Avenue NW, Grand Rapids, Michigan 49503, as ?Landlord?, and Corium International, Inc., a Delaware corporation, of 4558 40th Street SE, Grand Rapids, MI 49512, as ?Tenant?. Statement of Fa
May 13, 2016	EX-10.1	Fifth Amendment to License Agreement, by and between the Registrant and The Procter & Gamble Company, dated May 10, 2016. Exhibit 10.1 EXECUTION COPY Fifth Amendment to LICENSE AGREEMENT This Fifth Amendment to the License Agreement (the ?Fifth Amendment?) is effective as of May 10, 2016 (the, ?Effective Date?) between Corium International, Inc. (?Corium?) located at 235 Constitution Drive, Menlo Park, CA 94025, and The Procter and Gamble Company (hereinafter long with its Affiliates referred to as ?P&G?) located at
May 10, 2016	EX-99.1	# # # coriEx991 Exhibit 99.1 CORIUM REPORTS SECOND QUARTER FISCAL 2016 FINANCIAL RESULTS AND RECENT CORPORATE HIGHLIGHTS MENLO PARK, Calif., May 10, 2016 ? Corium International, Inc. (Nasdaq: CORI), a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal products, today announced unaudited financial results for the second fiscal
May 10, 2016	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 cori-20160510x8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): May 10, 2016 Corium International, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36375 38-3230774 (State or other jurisdiction
March 9, 2016	8-K	Submission of Matters to a Vote of Security Holders 8-K 1 cori-20160308x8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): March 8, 2016 Corium International, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36375 38-3230774 (State or other jurisdiction
February 22, 2016	8-K	Corium International 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): February 22, 2016 Corium International, Inc.
February 22, 2016	EX-99.2	Corplex™ Memantine TDS Phase 1 Interim Topline Results Exhibit 99.2 Corplex Memantine TDS Phase 1 Interim Topline Results Forward-looking Statements This presentation and the accompanying oral presentation contain forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, including statements regarding our business strategy, clinical trial timing and plans, the achievement of clinical and commercial mi
February 22, 2016	EX-99.1	Corium Announces Positive Topline Results from Phase 1 Clinical Study of Transdermal Corplex™ Memantine as a Potential Treatment of Alzheimer’s Disease Demonstrates Pharmacokinetic Profile Supporting the Feasibility of Sustained Transdermal Delivery Exhibit 99.1 Corium Announces Positive Topline Results from Phase 1 Clinical Study of Transdermal Corplex? Memantine as a Potential Treatment of Alzheimer?s Disease Demonstrates Pharmacokinetic Profile Supporting the Feasibility of Sustained Transdermal Delivery Webcast and Conference Call Today at 5:00 p.m. ET (2:00 p.m. PT) MENLO PARK, Calif., February 22, 2016 ? Corium International, Inc. (Nasd
February 12, 2016	SC 13G/A	CORI / Corium International, Inc. / SENZAR ASSET MANAGEMENT, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.
February 12, 2016	8-K	Entry into a Material Definitive Agreement 8-K 1 cori-20160212x8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): February 12, 2016 Corium International, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36375 38-3230774 (State or other jurisdic
February 12, 2016	EX-10.2	Additional form of restricted stock unit agreement under 2014 Equity Incentive Plan Exhibit 10.2 NOTICE OF RESTRICTED STOCK UNIT AWARD CORIUM INTERNATIONAL, INC. 2014 EQUITY INCENTIVE PLAN GRANT NUMBER: Unless otherwise defined herein, the terms defined in the Corium International, Inc. (the ?Company?) 2014 Equity Incentive Plan (the ?Plan?) shall have the same meanings in this Notice of Restricted Stock Unit Award (the ?Notice?) and the attached Award Agreement (Restricted Stock
February 12, 2016	S-8	Corium International S-8 coriCurrent FolioS8 As filed with the Securities and Exchange Commission on February 12, 2016 Registration No.
February 12, 2016	SC 13G/A	CORI / Corium International, Inc. / Broadfin Capital, LLC Passive Investment SC 13G/A 1 d703407713ga.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Corium International, Inc. (Name of Issuer) common stock, $0.001 par value per share (Title of Class of Securities) 21887L107 (CUSIP Number) December 31, 2015 (Date of Event Which Requires Filing of this Statement) Check the app
February 12, 2016	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ?Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended December 31, 2015 OR ?Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to . Commission File Number: 001-36375
February 12, 2016	EX-10.1	NNN L E A S E ARDENWOOD RESEARCH CENTER FREMONT, CALIFORNIA LBA REALTY FUND III-COMPANY VII, LLC, a Delaware limited liability company CORIUM INTERNATIONAL, INC., a Delaware corporation Exhibit 10.1 NNN L E A S E ARDENWOOD RESEARCH CENTER FREMONT, CALIFORNIA LANDLORD: LBA REALTY FUND III-COMPANY VII, LLC, a Delaware limited liability company TENANT: CORIUM INTERNATIONAL, INC., a Delaware corporation TABLE OF CONTENTS Page ARTICLE 1 - LEASE SUMMARY AND PROPERTY SPECIFIC PROVISIONS 1 ARTICLE 2 - LEASE 8 ARTICLE 3 - PREMISES 8 ARTICLE 4 - TERM AND POSSESSION 8 ARTICLE 5 - RENT 9 ART
February 8, 2016	EX-99.1	CORIUM REPORTS FIRST QUARTER FISCAL 2016 FINANCIAL RESULTS coriEx991 Exhibit 99.1 CORIUM REPORTS FIRST QUARTER FISCAL 2016 FINANCIAL RESULTS MENLO PARK, Calif., February 8, 2016 — Corium International, Inc. (Nasdaq: CORI), a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal products, today announced unaudited financial results from operations for the first fiscal quarter ended
February 8, 2016	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 cori-20160208x8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): February 8, 2016 Corium International, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36375 38-3230774 (State or other jurisdict
February 3, 2016	8-K	Regulation FD Disclosure, Financial Statements and Exhibits 8-K 1 a16-348718k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): February 3, 2016 Corium International, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36375 38-3230774 (State or other jurisdiction o
February 3, 2016	EX-99.1	Corium Announces Positive Topline Results from Phase 1 PK Clinical Study of Once-weekly Transdermal Corplex Donepezil as a Potential Treatment of Alzheimers Disease Demonstrates Sustained Delivery, Acceptable Skin Tolerability, and Pharmacokinetic Exhibit 99.1 Corium Announces Positive Topline Results from Phase 1 PK Clinical Study of Once-weekly Transdermal Corplex Donepezil as a Potential Treatment of Alzheimers Disease Demonstrates Sustained Delivery, Acceptable Skin Tolerability, and Pharmacokinetic Profile to Support the Feasibility of Once-weekly Dosing Webcast and Conference Call Today at 5:00 p.m. ET (2:00 p.m. PT) MENLO PARK, Cal
February 3, 2016	EX-99.2	Corplex™ Donepezil TDS Phase 1 Interim Topline Results Corium International, Inc. Exhibit 99.2 Corplex? Donepezil TDS Phase 1 Interim Topline Results Corium International, Inc. Forward-looking Statements This presentation and the accompanying oral presentation contain forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, including statements regarding our business strategy, clinical trial timing and plans, the achievement of
January 15, 2016	CORRESP	Corium International ESP CORIUM INTERNATIONAL, INC. 235 Constitution Drive Menlo Park, CA 94025 January 15, 2016 United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Attention: Scot Foley Mary Beth Breslin Division of Corporation Finance Re: Corium International, Inc. Registration Statement on Form S-3 Filed December 30, 2015 File No. 333-208800 Via EDGAR
January 14, 2016	DEF 14A	Corium International DEF 14A Use these links to rapidly review the document TABLE OF CONTENTS Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
December 30, 2015	S-3	As filed with the Securities and Exchange Commission on December 30, 2015 Table of Contents As filed with the Securities and Exchange Commission on December 30, 2015 Registration No.
December 30, 2015	8-K	Corium International 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): December 30, 2015 Corium International, Inc.
December 30, 2015	EX-12.1	CORIUM INTERNATIONAL, INC. Ratio of Earnings to Fixed Charges Exhibit 12.1 CORIUM INTERNATIONAL, INC. Ratio of Earnings to Fixed Charges Year Ended September 30, 2012 2013 2014 2015 Earnings (loss): Pre-tax income (loss) from continuing operations before adjustment for income (loss) from equity investees $ (5,450 ) $ (13,876 ) $ (9,911 ) $ (28,447 ) Plus: Fixed charges 5,247 7,705 6,961 7,446 Plus: Amortization of capitalized interest — — — — Distributed inc
December 30, 2015	EX-4.3	FORM OF DEBT SECURITY Exhibit 4.3 FORM OF DEBT SECURITY [Face of Security] CORIUM INTERNATIONAL, INC. [If applicable, insert—FOR PURPOSES OF THE ORIGINAL ISSUE DISCOUNT PROVISIONS OF THE INTERNAL REVENUE CODE OF 1986, THE ISSUE PRICE OF THIS SECURITY IS % OF ITS PRINCIPAL AMOUNT AT STATED MATURITY SET FORTH BELOW (ITS “PRINCIPAL AMOUNT”), THE AMOUNT OF ORIGINAL ISSUE DISCOUNT IS % OF ITS PRINCIPAL AMOUNT, THE YIELD TO
December 30, 2015	424B5	Corium International, Inc. Up to $20,000,000 of Shares Common Stock Use these links to rapidly review the document TABLE OF CONTENTS TABLE OF CONTENTS Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No.
December 30, 2015	EX-1.1	Controlled Equity Offering Sales Agreement dated December 30, 2015 EX-1.1 2 a15-252532ex1d1.htm EX-1.1 Exhibit 1.1 CORIUM INTERNATIONAL, INC. Shares of Common Stock (par value $0.001 per share) Controlled Equity OfferingSM Sales Agreement December 30, 2015 Cantor Fitzgerald & Co. 499 Park Avenue New York, NY 10022 Ladies and Gentlemen: Corium International, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cantor Fitzger
December 30, 2015	EX-4.4	CORIUM INTERNATIONAL, INC. , as Trustee Dated as of , Exhibit 4.4 CORIUM INTERNATIONAL, INC. And , as Trustee INDENTURE Dated as of , TABLE OF CONTENTS ARTICLE 1 - DEFINITIONS AND INCORPORATION BY REFERENCE 1 1.1 DEFINITIONS 1 1.2. OTHER DEFINITIONS 4 1.3. INCORPORATION BY REFERENCE OF TRUST INDENTURE ACT 5 1.4. RULES OF CONSTRUCTION 5 ARTICLE 2 - THE SECURITIES 5 2.1. ISSUABLE IN SERIES 5 2.2. ESTABLISHMENT OF TERMS OF SERIES OF SECURITIES 6 2.3. EX
December 16, 2015	EX-10.30	Amendment to Business Park Lease, by and between Registrant and David D. Bohannon Organization, dated September 9, 2015. EXHIBIT 10.30 AMENDMENT TO LEASE THIS AMENDMENT TO LEASE is made this 9th day of September, 2015 (the ?Amendment Effective Date?), between DAVID D. BOHANNON ORGANIZATION, a California corporation, herein referred to as "Landlord", and CORIUM INTERNATIONAL, INC., a Delaware corporation, herein referred to as "Tenant". WITNESSETH: WHEREAS, Landlord and Tenant entered into a Lease entitled "Business
December 16, 2015	EX-10.31	Amendment Agreement No. 1 to Amended and Restated Term Loan Agreement by and among the Registrant and certain entities affiliated with CRG, dated November 11, 2015. EX-10.31 4 cori-20150930ex1031b830f.htm EX-10.31 EXHIBIT 10.31 AMENDMENT AGREEMENT No. 1 THIS AMENDMENT AGREEMENT No. 1 (this “Amendment”), dated as of November 11, 2015, is made among Corium International, Inc., a Delaware corporation (the “Borrower”), and the Lenders listed on the signature pages hereof under the heading “LENDERS” (each a “Lender” and, collectively, the “Lenders”). The Borrower
December 16, 2015	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10‑K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10?K ? Annual Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended September 30, 2015 OR ? Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to . Commission File Number: 001?36375 Cori
December 16, 2015	EX-10.29	Offer Letter, accepted and agreed to on April 14, 2015, by and between the Registrant and Joseph J. Sarret. EX-10.29 2 cori-20150930ex1029635d3.htm EX-10.29 EXHIBIT 10.29 April 13, 2015 Joseph J. Sarret 130 Saint Germain Ave. San Francisco, CA 94114 Re: Offer of Employment by Corium International, Inc. Dear Joe, I am very pleased to present to you this offer of employment with Corium International, Inc. (the “Company”), in the position of Chief Business Officer of the Company, reporting to me, with an e
November 12, 2015	8-K	Corium International 8-K (Current Report/Significant Event) coriCurrentFolio8K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): November 11, 2015 Corium International, Inc.
November 12, 2015	EX-99.1	Corium Reports Fourth Quarter and Fiscal Year 2015 Financial Results and Year-End Highlights coriEx991 Exhibit 99.1 For Immediate Release Corium Reports Fourth Quarter and Fiscal Year 2015 Financial Results and Year-End Highlights MENLO PARK, Calif., November 12, 2015 - Corium International, Inc. (Nasdaq: CORI), a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal products, today announced unaudited financial r
September 11, 2015	8-K	Corium International 8-K (Current Report/Significant Event) coriCurrent folio8KItem101 - Lease UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): September 9, 2015 Corium International, Inc.
August 6, 2015	EX-99.1	Corium Prices Follow-On Offering of Common Stock Exhibit 99.1 Corium Prices Follow-On Offering of Common Stock MENLO PARK, Calif., August 5, 2015 ? Corium International, Inc. (Nasdaq:CORI), a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal products, today announced the pricing of its underwritten public offering of 4,000,000 shares of common stock at a public offer
August 6, 2015	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events 8-K 1 a15-1691518k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): August 5, 2015 Corium International, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36375 38-3230774 (State or other jurisdiction of
August 6, 2015	EX-1.1	4,000,000 Shares of Common Stock Corium International, Inc. UNDERWRITING AGREEMENT Exhibit 1.1 4,000,000 Shares of Common Stock Corium International, Inc. UNDERWRITING AGREEMENT August 5, 2015 JEFFERIES LLC LEERINK PARTNERS LLC As Representatives of the several Underwriters c/o JEFFERIES LLC 520 Madison Avenue New York, New York 10022 c/o LEERINK PARTNERS LLC 255 California Street, 12th Floor San Francisco, California 941111 Ladies and Gentlemen: Introductory. Corium Internation
August 6, 2015	424B5	4,000,000 Shares Corium International, Inc. Common Stock Use these links to rapidly review the document TABLE OF CONTENTS TABLE OF CONTENTS Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No.
August 3, 2015	424B5	4,000,000 Shares Corium International, Inc. Common Stock Use these links to rapidly review the document TABLE OF CONTENTS TABLE OF CONTENTS Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No.
July 30, 2015	EX-10.1	Second Amendment to Transdermal Fentanyl Agreements EX-10.1 2 cori-20150630ex1017af456.htm EX-10.1 Exhibit 10.1 [*] Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. Second Amendment to Transdermal Fentanyl Agreements This Second Amendment to the Transdermal Fenta
July 30, 2015	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ?Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2015 OR ?Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to . Commission File Number: 001-36375 Cor
July 29, 2015	EX-99.1	CORIUM REPORTS THIRD QUARTER FISCAL 2015 FINANCIAL RESULTS Conference Call and Webcast to Highlight Third Quarter Fiscal 2015 and Topline Results from MicroCor® PTH Phase 2a Clinical Trial coriEX991 Exhibit 99.1 CORIUM REPORTS THIRD QUARTER FISCAL 2015 FINANCIAL RESULTS Conference Call and Webcast to Highlight Third Quarter Fiscal 2015 and Topline Results from MicroCor? PTH Phase 2a Clinical Trial MENLO PARK, Calif., July 29, 2015 ? Corium International, Inc. (Nasdaq: CORI), a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of
July 29, 2015	8-K	Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): July 29, 2015 Corium International, Inc.
July 28, 2015	8-K	Regulation FD Disclosure, Financial Statements and Exhibits 8-K 1 a15-1642318k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): July 28, 2015 Corium International, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36375 38-3230774 (State or other jurisdiction of
July 28, 2015	EX-99.2	© 2015 Corium All Rights Reserved. Corium International, Inc. July 28, 2015 MicroCor hPTH(1-34) Phase 2a Interim Topline Results © 2015 Corium All Rights Reserved. Corium International, Inc. July 28, 2015 MicroCor hPTH(1-34) Phase 2a Interim Topline Results MicroCor Platform Overview ~10 mm ~200 µm ~40 mm Applicator Array Cross-Section MicroCor Operation Dissolvable Drug-in-Tip Insoluble Backing Layer Controlled Application Stratum Corneum Dermis Blood vessels Epidermis ~200µm Phase 2a Study Overview Part A Pharmacokinetics
July 28, 2015	EX-99.1	# # # Exhibit 99.1 Corium Announces Positive Topline Results from Phase 2a Study of Transdermal MicroCor? PTH in Post-Menopausal Women Demonstrates Rapid Drug Uptake, Significant Increases in Bone Formation Biomarkers and Excellent Skin Tolerability Company to Webcast Third Quarter Fiscal 2015 Results and Discussion of Topline Clinical Results on Wednesday, July 29th MENLO PARK, Calif., July 28, 2015 ?
July 2, 2015	8-K	Corium International 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): June 26, 2015 Corium International, Inc.
May 8, 2015	EX-4.3	FORM OF DEBT SECURITY EX-4.3 2 a15-108091ex4d3.htm EX-4.3 Exhibit 4.3 FORM OF DEBT SECURITY [Face of Security] CORIUM INTERNATIONAL, INC. [If applicable, insert—FOR PURPOSES OF THE ORIGINAL ISSUE DISCOUNT PROVISIONS OF THE INTERNAL REVENUE CODE OF 1986, THE ISSUE PRICE OF THIS SECURITY IS % OF ITS PRINCIPAL AMOUNT AT STATED MATURITY SET FORTH BELOW (ITS “PRINCIPAL AMOUNT”), THE AMOUNT OF ORIGINAL ISSUE DISCOUNT IS % OF
May 8, 2015	EX-12.1	CORIUM INTERNATIONAL, INC. Ratio of Earnings to Fixed Charges Exhibit 12.1 CORIUM INTERNATIONAL, INC. Ratio of Earnings to Fixed Charges Year Ended September 30, Six Months Ended March 31, 2012 2013 2014 2015 Earnings (loss): Pre-tax income (loss) from continuing operations before adjustment for income (loss) from equity investees $ (5,450 ) $ (13,876 ) $ (9,911 ) $ (13,899 ) Plus: Fixed charges 5,247 7,705 6,961 3,565 Plus: Amortization of capitalized inter
May 8, 2015	EX-4.4	CORIUM INTERNATIONAL, INC. , as Trustee Dated as of , Exhibit 4.4 CORIUM INTERNATIONAL, INC. And , as Trustee INDENTURE Dated as of , TABLE OF CONTENTS ARTICLE 1 - DEFINITIONS AND INCORPORATION BY REFERENCE 1 1.1 DEFINITIONS 1 1.2. OTHER DEFINITIONS 4 1.3. INCORPORATION BY REFERENCE OF TRUST INDENTURE ACT 5 1.4. RULES OF CONSTRUCTION 5 ARTICLE 2 - THE SECURITIES 5 2.1. ISSUABLE IN SERIES 5 2.2. ESTABLISHMENT OF TERMS OF SERIES OF SECURITIES 6 2.3. EX
May 8, 2015	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2015 OR o Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to . Commission File Number: 001-36375
May 8, 2015	S-3	Corium International S-3 Table of Contents As filed with the Securities and Exchange Commission on May 8, 2015 Registration No.
May 7, 2015	EX-99.1	CORIUM REPORTS SECOND QUARTER FISCAL 2015 FINANCIAL RESULTS Exhibit 99.1 CORIUM REPORTS SECOND QUARTER FISCAL 2015 FINANCIAL RESULTS MENLO PARK, Calif., May 7, 2015 (GLOBE NEWSWIRE) Corium International, Inc. (Nasdaq: CORI), a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal products, today announced unaudited financial results from operations for both the second fiscal quar
May 7, 2015	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 a15-1081218k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): May 7, 2015 Corium International, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36375 38-3230774 (State or other jurisdiction of in
May 1, 2015	EX-24.1	POWER OF ATTORNEY Unassociated Document Exhibit 24.1 POWER OF ATTORNEY KNOW ALL BY THESE PRESENTS, that the undersigned hereby constitutes and appoints Peter D. Staple, Robert S. Breuil, Christina Dickerson, and Timothy D. Sweemer, and each of them, his true and lawful attorney-in-fact to: (1) execute for and on behalf of the undersigned, in the undersigned?s capacity as a representative of Corium International, In
April 1, 2015	EX-99.1	CORIUM ANNOUNCES APPOINTMENT OF ERIC H. BJERKHOLT TO BOARD OF DIRECTORS Exhibit 99.1 For Immediate Release CORIUM ANNOUNCES APPOINTMENT OF ERIC H. BJERKHOLT TO BOARD OF DIRECTORS MENLO PARK, Calif., April 1, 2015 Corium International, Inc. (NASDAQ: CORI), a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal products, today announced the appointment of Eric H. Bjerkholt to the Companys Bo
April 1, 2015	8-K	Corium International 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): March 26, 2015 Corium International, Inc.
March 13, 2015	8-K	Corium International 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): March 12, 2015 Corium International, Inc.
February 17, 2015	SC 13D	CORI / Corium International, Inc. / ESSEX WOODLANDS HEALTH VENTURES FUND VII LP - SC 13D Activist Investment SC 13D SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) Corium International, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 21887L107 (CUSIP Number) Martin P. Sutter Essex Woodlands Healt
February 17, 2015	EX-99.1	JOINT FILING AGREEMENT EX-99.1 13D CUSIP: 21887L107 Exhibit 1 JOINT FILING AGREEMENT The undersigned acknowledge and agree that the foregoing statement on Schedule 13D is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13D shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing statements. The undersigned ackn
February 17, 2015	SC 13G/A	CORI / Corium International, Inc. / Broadfin Capital, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.
February 12, 2015	S-8	CORI / Corium International, Inc. S-8 - - S-8 As filed with the Securities and Exchange Commission on February 12, 2015 Registration No.
February 12, 2015	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended December 31, 2014 OR o Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to . Commission File Number: 001-363
February 10, 2015	EX-99.1	CORIUM REPORTS FIRST QUARTER FISCAL 2015 FINANCIAL RESULTS Exhibit 99.1 CORIUM REPORTS FIRST QUARTER FISCAL 2015 FINANCIAL RESULTS MENLO PARK, Calif., February 10, 2015 (GLOBE NEWSWIRE) — Corium International, Inc. (Nasdaq: CORI), a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal products, today announced unaudited financial results from operations for the first fiscal quart
February 10, 2015	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): February 10, 2015 Corium International, Inc.
January 21, 2015	DEF 14A	CORI / Corium International, Inc. DEF 14A - - DEF 14A Use these links to rapidly review the document TABLE OF CONTENTS Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
January 7, 2015	SC 13G	CORI / Corium International, Inc. / SENZAR ASSET MANAGEMENT, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.
December 15, 2014	EX-10.27	Amended and Restated Term Loan Agreement dated November 14, 2014, by and among the Registrant and certain entities affiliated with CRG. Exhibit 10.27 [EXECUTION VERSION] AMENDED AND RESTATED TERM LOAN AGREEMENT dated as of November 14, 2014 between Corium International, Inc. as Borrower, The SUBSIDIARY GUARANTORS from Time to Time Party Hereto, and Capital Royalty Partners II L.P., Capital Royalty Partners II ? Parallel Fund ?A? L.P., Capital Royalty Partners II - Parallel Fund ?B? (Cayman) L.P. and Capital Royalty Partners II (Ca
December 15, 2014	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Use these links to rapidly review the document TABLE OF CONTENTS Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
December 8, 2014	EX-99.1	CORIUM ANNOUNCES APPOINTMENT OF IVAN GERGEL, M.D. TO BOARD OF DIRECTORS EX-99.1 2 a14-257681ex99d1.htm EX-99.1 Exhibit 99.1 For Immediate Release CORIUM ANNOUNCES APPOINTMENT OF IVAN GERGEL, M.D. TO BOARD OF DIRECTORS MENLO PARK, Calif., December 8, 2014 — Corium International, Inc. (NASDAQ: CORI), a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal products, today announced the appointmen
December 8, 2014	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): December 4, 2014 Corium International, Inc.
November 20, 2014	8-K	Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): November 14, 2014 Corium International, Inc.
November 17, 2014	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): November 17, 2014 Corium International, Inc.
November 17, 2014	EX-99.1	CORIUM REPORTS FISCAL YEAR-END 2014 FINANCIAL RESULTS AND RECENT CORPORATE DEVELOPMENTS Exhibit 99.1 CORIUM REPORTS FISCAL YEAR-END 2014 FINANCIAL RESULTS AND RECENT CORPORATE DEVELOPMENTS MENLO PARK, Calif., November 17, 2014 (GLOBE NEWSWIRE) — Corium International, Inc. (Nasdaq: CORI), a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal products, today announced unaudited financial results for the fisca
September 17, 2014	EX-99.1	CORIUM ANNOUNCES APPOINTMENT OF PAUL GODDARD, PH.D. TO BOARD OF DIRECTORS Exhibit 99.1 For Immediate Release CORIUM ANNOUNCES APPOINTMENT OF PAUL GODDARD, PH.D. TO BOARD OF DIRECTORS MENLO PARK, Calif., September 17, 2014 — Corium International, Inc. (NASDAQ: CORI), a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal products, today announced the appointment of Paul Goddard, Ph.D. to the Com
September 17, 2014	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): September 15, 2014 Corium International, Inc.
August 12, 2014	EX-99.1	CORIUM REPORTS THIRD FISCAL QUARTER 2014 FINANCIAL RESULTS Exhibit 99.1 CORIUM REPORTS THIRD FISCAL QUARTER 2014 FINANCIAL RESULTS MENLO PARK, Calif., August 12, 2014 Corium International, Inc. (NASDAQ: CORI), a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal products, today announced unaudited results from operations for both the third fiscal quarter and the nine months e
August 12, 2014	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 a14-1895318k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): August 12, 2014 Corium International, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36375 38-3230774 (State or other jurisdiction o
August 12, 2014	EX-10.2	Amendment to Business Park Lease, by and between Registrant and David D. Bohannon Organization, dated July 19, 2014. Exhibit 10.2 AMENDMENT TO LEASE THIS AMENDMENT TO LEASE is made this 19th day of July, 2014, between DAVID D. BOHANNON ORGANIZATION, a California corporation, herein referred to as ?Landlord?, and CORIUM INTERNATIONAL, INC., a Delaware corporation, herein referred to as ?Tenant?. WITNESSETH: WHEREAS, Landlord and Tenant entered into a Lease entitled ?Business Park Lease? dated October 13, 2006, fo
August 12, 2014	EX-10.1	RESTATED SUPPLY AGREEMENT Contract Manufacturing for Teeth Whitening Strip Products EX-10.1 2 a14-142241ex10d1.htm EX-10.1 Exhibit 10.1 [*] Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. RESTATED SUPPLY AGREEMENT Contract Manufacturing for Teeth Whitening Strip Products This is an agreement (
August 12, 2014	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2014 OR o Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to . Commission File Number: 001-36375 C
July 24, 2014	8-K	Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): July 19, 2014 Corium International, Inc.
July 3, 2014	8-K	Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): June 30, 2014 Corium International, Inc.
May 14, 2014	EX-3.1	Restated Certificate of Incorporation Exhibit 3.1 CORIUM INTERNATIONAL, INC. RESTATED CERTIFICATE OF INCORPORATION (Pursuant to Sections 242 and 245 of the General Corporation Law of the State of Delaware) Corium International, Inc., a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the state of Delaware (the “General Corporation Law”), does hereby certify as follows. 1. The n
May 14, 2014	EX-3.2	Restated Bylaws Exhibit 3.2 CORIUM INTERNATIONAL, INC. a Delaware Corporation RESTATED BYLAWS As Adopted April 8, 2014 CORIUM INTERNATIONAL, INC. a Delaware Corporation RESTATED BYLAWS TABLE OF CONTENTS Page Article I - STOCKHOLDERS Section 1.1: Annual Meetings 1 Section 1.2: Special Meetings 1 Section 1.3: Notice of Meetings 1 Section 1.4: Adjournments 1 Section 1.5: Quorum 2 Section 1.6: Organization 2 Section
May 14, 2014	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2014 OR o Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to . Commission File Number: 001-36375
May 13, 2014	EX-99.1	CORIUM REPORTS SECOND FISCAL QUARTER 2014 FINANCIAL RESULTS Exhibit 99.1 CORIUM REPORTS SECOND FISCAL QUARTER 2014 FINANCIAL RESULTS MENLO PARK, Calif., May 13, 2014 — Corium International, Inc. (NASDAQ: CORI), a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal products, today announced unaudited results from operations for both the second fiscal quarter and the six months end
May 13, 2014	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): May 13, 2014 Corium International, Inc.
April 16, 2014	SC 13G	CORI / Corium International, Inc. / Broadfin Capital, LLC Passive Investment SC 13G 1 d147040413-g.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Corium International, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 21887L107 (CUSIP Number) April 3, 2014 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule
April 3, 2014	EX-4.6	STRATAGENT LIFE SCIENCES, INC. 2003 STOCK PLAN Exhibit 4.6 STRATAGENT LIFE SCIENCES, INC. 2003 STOCK PLAN 1. Purposes of the Plan. The purposes of this Plan are to attract and retain the best available personnel for positions of substantial responsibility, to provide additional incentive to Employees, Directors and Consultants and to promote the success of the Company’s business. Options granted under the Plan may be Incentive Stock Options or
April 3, 2014	S-8	- S-8 As filed with the Securities and Exchange Commission on April 3, 2014 Registration No.
April 3, 2014	424B4	6,500,000 Shares Corium International, Inc. Common Stock Use these links to rapidly review the document TABLE OF CONTENTS CORIUM INTERNATIONAL, INC.
April 2, 2014	S-1MEF	- S-1MEF As filed with the Securities and Exchange Commission on April 2, 2014 Registration No.
March 31, 2014	CORRESP	- March 31, 2014 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.
March 31, 2014	CORRESP	- CORIUM INTERNATIONAL, INC. 235 Constitution Drive Menlo Park, CA 94025 March 31, 2014 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Attention: Jeffrey P. Reidler, Assistant Director Scot Foley, Staff Attorney Division of Corporation Finance Re: Corium International, Inc. Form S-1 Registration Statement on Form S-1

CORI / Corium International, Inc. - Pemfailan SEC, Laporan Tahunan, Penyata Proksi

Statistik Asas

SEC Filings

SEC Filings (Chronological Order)